Profile data is unavailable for this security.

About the company

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

  • Revenue in USD (TTM)48.63bn
  • Net income in USD-1.66bn
  • Incorporated--
  • Employees104.71k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301
  • Fax+49 2 143066328
  • Websitehttps://www.bayer.de/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BAYX.N:GER since
Bluerock Therapeutics LPAnnounced08 Aug 201908 Aug 2019Announced27.89%600.00m
Maty's Healthy Products LLCDeal completed11 Jul 201911 Jul 2019Deal completed26.45%--
Data delayed at least 15 minutes, as of Jan 17 2020 16:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Merck KGaA17.36bn1.27bn16.55bn54.04k44.032.835.130.95342.627.9635.9841.760.40251.944.86302,786.502.964.543.905.9863.1366.097.3511.031.085.400.40839.902.205.98-57.97-2.2814.485.64
Shionogi & Co Ltd3.24bn1.15bn20.49bn5.23k17.583.2315.576.33405.18405.181,141.932,208.950.46791.447.6668,105,300.0016.6113.2118.4315.0783.7177.7235.4926.766.31--0.001126.565.534.6521.9526.73-12.1115.36
Otsuka Holdings Co Ltd12.46bn1.06bn24.85bn32.94k23.571.5414.411.99208.24208.242,532.433,189.110.52892.703.7441,677,970.004.63--5.68--67.28--8.75--1.95--0.1572--4.20---26.67------
Alexion Pharmaceuticals, Inc.4.74bn1.36bn25.07bn2.66k18.772.4214.365.296.046.5321.0746.850.33050.7474.671,782,982.009.503.2410.253.5192.0490.4328.7310.963.4523.890.20130.0016.3421.64-95.69-39.1548.67--
Astellas Pharma Inc11.89bn2.24bn32.78bn16.24k14.722.7811.662.76129.85129.85689.28687.450.67741.933.9880,633,010.0012.7710.3416.8213.4378.0675.9018.8514.301.46--0.113537.460.46392.7634.9719.59-1.477.07
Chugai Pharmaceutical Co Ltd6.01bn1.27bn53.68bn7.43k41.507.11--8.93254.58254.581,208.131,485.300.69121.623.5889,100,910.0014.578.4017.359.9359.2552.3221.0813.072.80--0.0050.538.536.4827.2012.6939.019.86
Takeda Pharmaceutical Co Ltd26.12bn142.00m63.44bn49.58k138.091.4212.652.4332.1032.102,130.243,123.560.33541.864.6458,025,380.000.18431.360.21551.7765.2269.830.54943.830.93820.47140.5078226.3318.454.39-41.610.458611.300.00
Bayer AG (ADR)48.63bn-1.66bn82.32bn104.71k--1.5320.731.69-0.4237-0.359412.3913.660.33571.733.74415,634.60-1.144.12-1.395.2857.4258.83-3.398.160.88264.110.486969.6713.05-0.286-47.83-11.873.75--
Novartis AG49.56bn7.21bn243.10bn109.00k31.024.1518.974.903.004.9120.6222.450.38292.216.04383,391.805.576.817.138.4170.9066.5514.5517.420.728357.900.364174.616.050.170265.026.53-0.13660.9933
Data as of Jan 17 2020. Currency figures normalised to Bayer AG's reporting currency: US Dollar USD

Institutional shareholders

0.12%Per cent of shares held by top holders
HolderShares% Held
Parametric Portfolio Associates LLCas of 30 Sep 20192.61m0.07%
Academy Capital Management, Inc.as of 30 Sep 2019969.15k0.03%
Pacer Advisors, Inc.as of 30 Sep 2019399.99k0.01%
AMG National Trust Bankas of 30 Sep 2019184.24k0.01%
Tocqueville Asset Management LPas of 31 Dec 2019177.20k0.01%
Pillar Pacific Capital Management LLCas of 30 Sep 2019116.88k0.00%
DWS Investment Management Americas, Inc.as of 30 Nov 2019111.01k0.00%
Cheviot Value Management LLCas of 30 Sep 2019100.67k0.00%
Strategic Advisers LLCas of 30 Nov 201988.63k0.00%
Ally Financial, Inc. (Investment Management)as of 30 Sep 201975.00k0.00%
More ▼
Data from 30 Sep 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.